Scholars@Duke

Atorvastatin is similarly effective in all ischemic stroke subtypes: Secondary analysis of the SPARCL trial

Publication ,  Conference
Amarenco, P; Benavente, O; Goldstein, LB; Callahan, A; Hennerici, MG; Sillesen, H; Welch, KM; Zivin, J
Published in: STROKE
February 1, 2008
Link to item

Duke Scholars

Larry Bruce Goldstein
Author Larry Bruce Goldstein Neurology, Stroke and Vascular Neurology

Published In

STROKE

ISSN

0039-2499

Publication Date

February 1, 2008

Volume

39

Issue

2

Start / End Page

556 / 556

Location

New Orleans, LA

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Conference Name

33rd International Stroke Conference

Related Subject Headings

  • Neurology & Neurosurgery
  • 1109 Neurosciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Amarenco, P., Benavente, O., Goldstein, L. B., Callahan, A., Hennerici, M. G., Sillesen, H., … Zivin, J. (2008). Atorvastatin is similarly effective in all ischemic stroke subtypes: Secondary analysis of the SPARCL trial. In STROKE (Vol. 39, pp. 556–556). New Orleans, LA: LIPPINCOTT WILLIAMS & WILKINS.
Amarenco, Pierre, Oscar Benavente, Larry B. Goldstein, Alfred Callahan, Michael G. Hennerici, Henrik Sillesen, K. M. Welch, and Justin Zivin. “Atorvastatin is similarly effective in all ischemic stroke subtypes: Secondary analysis of the SPARCL trial.” In STROKE, 39:556–556. LIPPINCOTT WILLIAMS & WILKINS, 2008.
Amarenco P, Benavente O, Goldstein LB, Callahan A, Hennerici MG, Sillesen H, et al. Atorvastatin is similarly effective in all ischemic stroke subtypes: Secondary analysis of the SPARCL trial. In: STROKE. LIPPINCOTT WILLIAMS & WILKINS; 2008. p. 556–556.
Amarenco, Pierre, et al. “Atorvastatin is similarly effective in all ischemic stroke subtypes: Secondary analysis of the SPARCL trial.” STROKE, vol. 39, no. 2, LIPPINCOTT WILLIAMS & WILKINS, 2008, pp. 556–556.
Amarenco P, Benavente O, Goldstein LB, Callahan A, Hennerici MG, Sillesen H, Welch KM, Zivin J. Atorvastatin is similarly effective in all ischemic stroke subtypes: Secondary analysis of the SPARCL trial. STROKE. LIPPINCOTT WILLIAMS & WILKINS; 2008. p. 556–556.

Published In

STROKE

ISSN

0039-2499

Publication Date

February 1, 2008

Volume

39

Issue

2

Start / End Page

556 / 556

Location

New Orleans, LA

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Conference Name

33rd International Stroke Conference

Related Subject Headings

  • Neurology & Neurosurgery
  • 1109 Neurosciences
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology